Rachid KaramMD, PhD
Dr. Rachid Karam obtained his medical degree in Brazil, at the Federal University of Health Sciences of Porto Alegre, one of the most reputable medical schools in the country. He has a Ph.D. in Oncogenetics, and focused his graduate studies on the regulation of the CDH1 gene expression in Hereditary Diffuse Gastric Cancer patients, at the University of Porto, in Europe, and at MD Anderson Cancer Center, Houston, Texas. He did his postdoctoral studies at the University of California, San Diego (UCSD) School of Medicine, where he performed RNA biology research.
He joined Ambry Genetics in 2014 and is now the Associate Director of Ambry’s Translational Genomics (ATG) Lab. Additionally, he is currently the Chair of the CDH1 ClinGen expert panel, a National Institutes of Health (NIH)-funded resource dedicated to building a central resource that defines the clinical relevance of CDH1 genomic alterations for use in precision medicine and research.